Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | FGF1 | P05230 | 3/20 | 0.45 |
| ▸ | FGF2 | P09038 | 3/20 | 0.45 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.45 |
| ▸ | VEGFA | P15692 | 1/20 | 0.45 |
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.44 |
| ▸ | GJB2 | P29033 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.41 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.41 |
| ▸ | MDK | P21741 | 1/20 | 0.40 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.39 |
| ▸ | SELP | P16109 | 1/20 | 0.38 |
| ▸ | IGF2R | P11717 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18164225 | 0.95 | MMP13 (0.48) | MMP13FGF1FGF2HPSEVEGFA | |
| SCHEMBL16644793 | 0.95 | MMP13 (0.47) | MMP13FGF1FGF2HPSEVEGFA | |
| SCHEMBL18056109 | 0.95 | MMP13 (0.47) | MMP13FGF1FGF2HPSEVEGFA | |
| SCHEMBL16644781 | 0.95 | MMP13 (0.47) | MMP13FGF1FGF2HPSEVEGFA | |
| SCHEMBL16644879 | 0.95 | MMP13 (0.47) | MMP13FGF1FGF2HPSEVEGFA | |
| SCHEMBL16644895 | 0.95 | MMP13 (0.47) | MMP13FGF1FGF2HPSEVEGFA | |
| SCHEMBL16092086 | 0.94 | MMP13 (0.48) | MMP13FGF1FGF2HPSEVEGFA | |
| SCHEMBL18051731 | 0.94 | MMP13 (0.47) | MMP13FGF1FGF2HPSEVEGFA | |
| SCHEMBL16640875 | 0.93 | MMP13 (0.49) | MMP13FGF1FGF2HPSEVEGFA | |
| SCHEMBL16640824 | 0.93 | MMP13 (0.49) | MMP13FGF1FGF2HPSEVEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301083-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301083-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | MMP13 707/4885FGF1 1398/4885FGF2 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.